The USFDA has recently approved the citrate-free adalimumab biosimilar, adalimumab-aacf, for the treatment of chronic autoimmune diseases. The drug is a TNF blocker and is indicated for a range of autoimmune disorders. It will be launched as a self-administrable syringe or an autoinjector pen. The approval was granted after the biosimilar showed similar efficacy and safety profile as the original drug.
Recommended dosage: The biosimilar is available as a prefilled 40mg/0.8 ml autoinjector pen or glass syringe. The recommended dosage for most autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, is 40 mg administered subcutaneously every other week. For adult and pediatric patients (6 years and older and weighing at least 40 kg) with Crohn’s disease 160 mg on day 1, 80 mg on day 15, followed by a 40 mg dose every two weeks from day 29…
